Bloomberg
J&J Blood-Clot Pause Done to Educate Doctors, Seek Other Cases
(Bloomberg) — U.S. health officials urged a pause on the use of Johnson & Johnson’s Covid-19 vaccine due to dangerous blood-clotting to give them time to educate doctors on how to treat the exceedingly rare disorder and to “look in all the nooks and crannies” for other cases.That’s the message from Peter Marks, a top official at the U.S. Food and Drug Administration, after six women between the ages of 18 and 48 developed a severe form of blood clotting in the brain called cerebral venous sinus thrombosis with low levels of blood platelets and federal officials responded by suggesting that use of the one-shot vaccine be paused. As of Monday, the U.S. had administered almost 7 million J&J doses.At least one woman died, and a second woman was in critical condition, officials said. The normal treatment for clots, the blood-thinner heparin, could make the disorder worse, or even kill a patient, health officials said Tuesday.“Everyone knew it could cause a hit to vaccine confidence,” said Marks, the head of the FDA’s Center for Biologics Evaluation and Research, speaking Tuesday at an American Medical Association webinar. Though the cases “could just be a statistical aberration,” the health authorities sought to exercise an abundance of caution, he said.The safety signals, he said, were seen between 6 and 13 days after vaccination and were identified by the FDA through a government-run vaccine adverse event reporting system.At a briefing earlier in the day, Anne Schuchat, principal deputy director at the Centers for Disease Control and Prevention, said those vaccinated a month ago are at low risk, but people who got it in the last couple of weeks should be on the lookout for headache, leg pain, abdominal pain and shortness of breath.“We expect it to be a matter of days for this pause,” the FDA’s Janet Woodcock said at the briefing.6.8 Million DosesMore than 6.8 million doses of the single-shot J&J vaccine have been administered in the U.S. through Monday. Jeff Zients, the White House Covid-19 response coordinator, said the delay won’t have a significant impact on the Biden administration’s vaccination plans.Walgreens Boots Alliance Inc. and CVS Health Corp., which have been administering the shot in drugstores, both said they would pause immediately.A number of states on Tuesday also said they would follow the recommendation. New York plans to immunize people who were supposed to receive J&J’s shot with Pfizer’s vaccine at state-run mass vaccination sites. Virginia said it will reschedule appointments.Shereef Elnahal, the CEO of University Hospital and former commissioner of the New Jersey Department of Health, said he’s awaiting further information as to whether younger women or another sub-population are more susceptible to the extremely rare disorder, and whether or not it was caused by the vaccine or mere coincidence.“We are in a limbo period where we just don’t know enough to present all the facts to the community,” Elnahal said in an interview.“This is a vaccine that is very effective for what matters most, preventing hospitalization and death,” he added, noting that if the FDA extended a universal, indefinite pause, it would limit the tools at the health-system’s disposal to curb the pandemic.Crucial JunctureThe decision comes at a crucial juncture in the U.S. vaccination effort, which has gained speed in recent weeks at the same time a worsening outbreak driven by coronavirus variants grips the upper Midwest. It could boost vaccine hesitancy in the U.S. and heighten worry about vaccines globally after similar issues caused delays with AstraZeneca Plc’s shot.Schuchat emphasized at the briefing that the clotting events with low platelet counts are not being seen with Pfizer Inc.-BioNTech SE vaccine and the Moderna Inc. shot.J&J shares closed down 1.3% at $159.48 in New York trading.No definitive cause for the disorder has yet been determined, according to Marks, who said it was very similar to blood clotting incidents seen with the AstraZeneca Plc vaccine. It may be tied to an immune response after vaccination that leads to an activation of platelets and clotting, he said.The J&J shot has been popular due to its single dose while the Pfizer and Moderna vaccines require two doses spaced several weeks apart. Many of the J&J doses in the U.S. have been targeted to harder-to-reach populations through the federal government’s distribution program that works through pharmacies, federally qualified health centers and other locations.“We are recommending a pause in the use of this vaccine out of an abundance of caution,” the CDC and the FDA said in a joint statement Tuesday. The CDC will convene a meeting Wednesday of its Advisory Committee on Immunization Practices to review the cases and assess their potential significance.The FDA will review the CDC assessment as it also investigates these cases, according to the statement.Still, “the potential complications with some of these blood clots is statistically much, much lower than the number of blood clots that we see on an annual basis in this country,” said Mario Ramirez, an emergency medicine physician who served as acting director of the Department of Health and Human Services’ Office of Global Affairs Office of Pandemic and Emerging Threats under the Obama Administration.“We need to just take a deep breath and give investigators a chance to look at what the data says before we can draw any conclusions,” Ramirez said in an interview with Bloomberg Radio.European RolloutJ&J has recently begun shipments to the European Union. The bloc’s drugs regulator, the European Medicines Agency, didn’t immediately respond to a request for comment. J&J said in a statement that it’s decided to delay the rollout of its vaccine in Europe.The EMA said Friday that it is assessing blood clots in people who received the J&J vaccine, after four serious cases of unusual clots accompanied by low blood platelets, one of which was fatal, emerged.On Friday afternoon, FDA spokesperson Abby Capobianco said in an emailed statement that the agency hadn’t found a causal relationship between the J&J vaccine and the six cases of thromboembolic events, and was continuing its assessment of the cases“Our analysis of the data will inform the potential need for regulatory action,” she said. The agency had shared information with the EMA, which became “the basis” of the EU probe, she said.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
